Impact of Personalized Dosing of Faricimab on Treatment Outcomes in nAMD

Video

Dr Varun Chaudhary discusses the impact of personalized treat-and-extend-based dosing on visual and anatomic outcomes of faricimab in the TENAYA and LUCERNE clinical trials in neovascular AMD.

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Subscribe Now!
Recent Videos
At ARVO 2025, Christine Kay, MD, shares interim results from the PRISM trial population extension cohort
Related Content
LumiThera announces top-line results from LIGHTSITE IIIB extension trial assessing the Valeda Light Delivery System

LumiThera announces top-line results from LIGHTSITE IIIB extension trial assessing the Valeda Light Delivery System

Jordana Joy
May 15th 2025
Article
Q&A: Katherine Talcott, MD, on exploring a potential connection between autoimmune diseases and AMD

Q&A: Katherine Talcott, MD, on exploring a potential connection between autoimmune diseases and AMD

Sydney M Crago
May 11th 2025
Article
Optigo Bio receives People’s Choice Award for its proprietary drug anchoring

Optigo Bio receives People’s Choice Award for its proprietary drug anchoring

Kassi Filkins
May 9th 2025
Article
Galimedix Therapeutics completes single ascending dose portion of phase 1 trial assessing GAL-101

Galimedix Therapeutics completes single ascending dose portion of phase 1 trial assessing GAL-101

Jordana Joy
May 7th 2025
Article
Phase 2 BETTER trial results shared at ARVO 2025

Phase 2 BETTER trial results shared at ARVO 2025

Sydney M Crago
May 7th 2025
Article
Innovent Biologics announced latest data on IBI302

Innovent Biologics announced latest data on IBI302

Kassi Filkins
May 7th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.